The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
News|Slideshows|January 18, 2024
Top 10 Diets for 2024: US News & World Report Rankings
Author(s)Sydney Jennings
US News and World Report released its annual “Best Diets” rankings for 2024. Out of 30 of the most popular diets ranked by health experts, these 10 came out on top.
Advertisement
US News and World Report recently released its annual
Advertisement
Related to this article
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
Advertisement
Advertisement
Trending on Patient Care Online
1
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
2
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
5